参考文献/References:
[1]Chimowitz MI,Lynn MJ,Derdeyn CP,et al.Stenting versus aggressive medical therapy for intracranial arterial stenosis.N Engl J Med,2011,365(11):993-1003.
[2]Wang Y,Zhao X,Liu L,et al.Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China:the Chinese Intracranial Atherosclerosis (CICAS) Study.Stroke,2014,45(3):663-669.
[3]Gutierrez J,Turan TN,Hoh BL,et al.Intracranial atherosclerotic stenosis:risk factors,diagnosis,and treatment.Lancet Neurol,2022,21(4):355-368.
[4]Dearborn JL,Zhang Y,Qiao Y,et al.Intracranial atherosclerosis and dementia:the Atherosclerosis Risk in Communities (ARIC) Study.Neurology,2017,88(16):1556-1563.
[5]Henkes H,Miloslavski E,Lowens S,et al.Treatment of intracranial atherosclerotic stenoses with balloon dilatation and selfexpanding stent deployment (WingSpan).Neuroradiology,2005,47(3):222-228.
[6]Alexander MJ,Zauner A,Chaloupka JC,et al.WEAVE trial:final results in 152 onlabel patients.Stroke,2019,50(4):889-894.
[7]Yamaga H,Tsuboko Y,Terada T,et al.Comprehensive risk analysis of the Wingspan stent in relation to target vessels.J Neuroendovasc Ther,2022,16(9):458-466.
[8]Gao P,Wang T,Wang D,et al.Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis:the CASSISS randomized clinical trial.JAMA,2022,328(6):534-542.
[9]Zaidat OO,Fitzsimmons BF,Woodward BK,et al.Effect of a balloonexpandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis:the VISSIT randomized clinical trial.JAMA,2015,313(12):1240-1248.
[10]Miao Z,Jiang L,Wu H,et al.Randomized controlled trial of symptomatic middle cerebral artery stenosis:endovascular versus medical therapy in a Chinese population.Stroke,2012,43(12):3284-3290.
[11]Luo J,Wang T,Yang K,et al.Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis.Cochrane Database Syst Rev,2023,2(2):CD013267.
[12]Zhong C,Chen S,Zhang J,et al.Intracranial angioplasty with a selfexpandable stent for intracranial atherosclerotic stenosis:systematic review and metaanalysis.Front Neurol,2023,13:1074228.
[13]Higashida RT,Halbach VV,Dowd CF,et al.Initial clinical experience with a new selfexpanding nitinol stent for the treatment of intracranial cerebral aneurysms the Cordis Enterprise stent.AJNR Am J Neuroradiol,2005,26(7):1751-1756.
[14]Levy EI,Turk AS,Albuquerque FC,et al.Wingspan instent restenosis and thrombosis:incidence,clinical presentation,and management.Neurosurgery,2007,61(3):644-650.
[15]Turk AS,Levy EI,Albuquerque FC,et al.Influence of patient age and stenosis location on Wingspan instent restenosis.AJNR Am J Neuroradiol,2008,29(1):23-27.
[16]Vajda Z,Schmid E,Güthe T,et al.The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent.Neurosurgery,2012,70(1):91-101.
[17]Wang X,Wang Z,Wang C,et al.Application of the Enterprise stent in atherosclerotic intracranial arterial stenosis:a series of 60 cases.Turk Neurosurg,2016,26(1):69-76.
[18]Feng Z,Duan G,Zhang P,et al.Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis:an initial experience of 44 patients.BMC Neurol,2015,15:187.
[19]Sun B,Xu C,Wu P,et al.Intracranial angioplasty with Enterprise stent for intracranial atherosclerotic stenosis:a singlecenter experience and a systematic review.Biomed Res Int,2021,2021:6645500.
[20]Lee KY,Chen DY,Hsu HL,et al.Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise:evaluation of clinical and vascular outcome.Interv Neuroradiol,2016,22(2):187-195.
[21]Zhang K,Li TX,Wang ZL,et al.Factors affecting instent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases.Sci Rep,2021,11(1):10479.
[22]Cui R,Yan L,Kang K,et al.Longterm outcome of Enterprise stenting for symptomatic ICAS in a highvolume stroke center.Front Neurol,2021,12:672662.
[23]Salik AE,Selcuk HH,Zalov H,et al.Mediumterm results of undersized angioplasty and stenting for symptomatic highgrade intracranial atherosclerotic stenosis with Enterprise.Interv Neuroradiol,2019,25(5):484-490.
[24]Jung WS,Kim SS,Lee KY,et al.Usefulness of selfexpandable stent for recanalization of intracranial atherosclerotic disease:preliminary experience with Enterprise stent.Neurointervention,2022,17(1):37-44.
[25]Huang CM,Hong YF,Xing SH,et al.Thirtyday outcomes of the Enterprise stent in treating hypoperfusion of symptomatic intracranial stenosis.World Neurosurg,2019,129:e429-e435.
[26]Wang N,Lu Y,Feng L,et al.Identifying risk factors for instent restenosis in symptomatic intracranial atherosclerotic stenosis:a systematic review and metaanalysis.Front Neurol,2023,14:1170110.
[27]Zhou ZL,Li TX,Zhu LF,et al.Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis.Eur J Med Res,2023,28(1):286.
[28]Sarathy D,Elghareeb M,Clark A,et al.Update on clinical management with neurovascular stents.J Exp Neurol,2022,3(2):49-59.
[29]Zhao Z,Liang W,Yan L,et al.Optional or optimal?Offlabel stenting for intracranial atherosclerotic stenosis:a scoping review.Interv Neuroradiol,2023 Apr 26.Epub ahead of print.
[30]Du Z,Mang J,Yu S,et al.Weighing in on the offlabel use:initial experience of neuroform EZ stenting for intracranial arterial stenosis in 45 patients.Front Neurol,2018,9:852.
[31]Xu H,Quan T,Zaidat OO,et al.Neuroform EZ stenting for symptomatic intracranial artery stenosis:30 days outcomes in a highvolume stroke center.Front Neurol,2019,10:428.
[32]贾子昌,卞焕菊,李选,等.Neuroform EZ支架在治疗复杂症状性颅内动脉重度狭窄中的应用.北京大学学报(医学版),2019,51(5):835-839.
[33]张荣举,王君,曹向宇,等.Neuroform EZ支架及Solitaire AB支架在颅内动脉粥样硬化性重度狭窄治疗中的应用.中华解剖与临床杂志,2021,26(4):391-396.
[34]Li H,Zhang L,Wang P,et al.The safety and efficacy of the Neuroform EZ stent for the treatment of symptomatic atherosclerotic stenosis in the middle cerebral artery.Clin Imaging,2022,82:210-215.
[35]范承哲,王力锋,马玉栋,等.Neuroform EZ支架在重度颅内动脉粥样硬化性狭窄患者中的初步临床研究.中华内科杂志,2022,61(3):304-309.
[36]Zhou K,Cao Y,He XH,et al.A comparison of safety and effectiveness between Wingspan and Neuroform stents in patients with middle cerebral artery stenosis.Front Neurol,2021,12:527541.
[37]Jankowitz BT,Hanel R,Jadhav AP,et al.Neuroform Atlas Stent System for the treatment of intracranial aneurysm:primary results of the Atlas Humanitarian Device Exemption cohort.J Neurointerv Surg,2019,11(8):801-806.
[38]Takayanagi A,Cheng PK,Feng L.A novel technique for stenting of intracranial stenosis using the Neuroform Atlas stent and Gateway balloon catheter.Interv Neuroradiol,2021,27(6):770-773.
[39]Memon MZ,Ezzeldin M,Biswas A,et al.Novel technique of stent placement via gateway balloon in intracranial atherosclerosisassociated large vessel occlusion.J Neuroimaging,2023,33(5):773-780.
[40]Buonomo O,Mormina E,Caragliano AA,et al.Safety and effect of Neuroform Atlas stent in the treatment of symptomatic intracranial stenosis:a singlecenter experience.Heliyon,2021,7(9):e08040.
[41]Ellenbogen Y,Hendriks EJ,Karadimas S,et al.Use of the neuroform atlas for stenting of intracranial atherosclerotic disease:clinical and angiographic outcomes.Interv Neuroradiol,2023 Oct 10.Epub ahead of print.
[42]Duan G,Feng Z,Zhang L,et al.Solitaire stents for the treatment of complex symptomatic intracranial stenosis after antithrombotic failure:safety and efficacy evaluation.J Neurointerv Surg,2016,8(7):680-684.
[43]Cao X,Wang J,Tian C,et al.Solitaire AB stentangioplasty for stenoses in perforator rich segments:a singlecenter experience.Interv Neuroradiol,2020,26(5):608-614.
[44]Tang H,Lu Z,Zeng Z,et al.Endovascular treatment of symptomatic intracranial atherosclerotic stenosis with low profile visualized intraluminal support stent.J Clin Neurosci,2021,90:256-261.
[45]Wang JW,Li XY,Li CH,et al.Safety and efficacy of the LowProfile Visualized Intraluminal Support stent in treating intracranial atherosclerotic stenosis.Neurologia (Engl Ed),2023,38(8):521-529.